Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats

American Journal of Hypertension

Volumn 27, Issue 5, 2014, Pages 720-726

  Freundlich, Michael ^a   Li, Yan C ^b   Quiroz, Yasmir ^c   Bravo, Yanauri ^c   Seeherunvong, Wacharee ^a   Faul, Christian ^a   Weisinger, Jose R ^a   Rodriguez Iturbe, Bernardo ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c HOSPITAL UNIVERSITARIO DE MARACAIBO   (Venezuela)

Author keywords

cardiac hypertrophy; fibroblast growth factor; paricalcitol.; renin angiotensin system; uremia; Vitamin D

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSINOGEN; BRAIN NATRIURETIC PEPTIDE; CREATININE; ENALAPRIL; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MESSENGER RNA; PARICALCITOL; RENIN; VITAMIN D; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERGOCALCIFEROL; FGFR1 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOWN REGULATION; EXPERIMENTAL CARDIAC HYPERTROPHY; HEART LEFT VENTRICLE HYPERTROPHY; KIDNEY FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; QUANTITATIVE ANALYSIS; RAT; RECEPTOR GENE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; UREMIA; ANIMAL; BLOOD PRESSURE; CARDIOMEGALY; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HEART MUSCLE; HYPERTENSION; METABOLISM; NEPHRECTOMY; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOMEGALY; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENALAPRIL; ERGOCALCIFEROLS; FIBROBLAST GROWTH FACTORS; HYPERTENSION; MALE; MYOCARDIUM; NEPHRECTOMY; RATS, SPRAGUE-DAWLEY; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER; UREMIA;

EID: 84887224544     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt177     Document Type: Article

References (38)

1. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47:186-192.
2. Shrof R, Weaver DJ Jr, Mitsnefes MM. Cardiovascular complications in children with chronic kidney disease. Nat Rev. Nephrol 2011; 7:642-649.
3. London GM. Lef ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 2002; 17(Suppl):29-36.
4. Husain K, Ferder L, Mizobuchi M, Finch J, Slatopolsky E. Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am J Nephrol 2009; 29:465-472.
5. Siedlecki AM, Jin X, Muslin AJ. Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int 2009; 75:800-808.
6. Tyralla K, Adamczak M, Benz K, Campean V, Gross ML, Hilgers KF, Ritz E, Amann K. High-dose enalapril treatment reverses myocar-dial fbrosis in experimental uremic cardiomyopathy. Plos One 2011; 6:e15287.
7. Custódio MR, Koike MK, Neves KR, dos Reis LM, Graciolli FG, Neves CL, Batista DG, Magalhães AO, Hawlitschek P, Oliveira IB, Dominguez W V, Moysés RM, Jorgetti V. Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system. Nephrol Dial Transplant 2012; 27:1437-1445.
8. Li YC. Vitamin D: roles in renal and cardiovascular protection. Curr Opin Nephrol Hypertens 2012; 21:72-79.
9. Mizobuchi M, Nakamura H, Tokumoto M, Finch J, Morrissey J, Liapis H, Slatopolsky E. Myocardial efects of VDR activators in renal failure. J Steroid Biochem Mol Biol 2010; 121(1-2):188-192.
10. Helvig CF, Cuerrier D, Hosfeld CM, Ireland B, Kharebov AZ, Kim J W, Ramjit NJ, Ryder K, Tabash SP, Herzenberg AM, Epps TM, Petkovich M. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int 2010; 78:463-472.
11. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71:31-38.
12. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Tadhani R. Survival of patients undergoing hemodialysis with paricalcitol or cal-citriol therapy. N Engl J Med 2003; 349:446-456.
13. Kim HW, Park C W, Shin YS, Kim YS, Shin SJ, Kim YS, Choi EJ, Chang YS, Bang BK. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract 2006; 102:c21-29.
14. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao L P. 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110:229-238.
15. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1, 25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Ki d n e y In t 2008; 74:170-179.
16. Kong J, Kim GH, Wei M, Sun T, Li G, Liu SQ, Li X, Bhan I, Zhao Q, Tadhani R, Li YC. Terapeutic efects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Am J Pathol 2010; 177:622-631.
17. Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, Cohen R, Klopot A, Zhang Z, Li YC. 1, 25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007; 282:29821-29830.
18. Fryer RM, Rakestraw PA, Nakane M, Dixon D, Banfor PN, Koch KA, Wu-Wong JR, Reinhart GA. Diferential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron Physiol 2007; 106:76-81.
19. Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC, Rodriguez-Iturbe B. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008; 74:1394-1402.
20. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86:747-803.
21. Wollert KC, Drexler H. Te renin-angiotensin system and experimental heart failure. Cardiovasc Res 1999; 43:838-849.
22. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of FgF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113:561-568.
23. De Borst MH, Vervloet MG, ter Wee PM, Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 2011; 22:1603-1609.
24. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hofmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M. Fibroblast growth factor 23 and lef ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119:2545-2552.
25. Seeherunvong W, Abitbol CL, Chandar J, Rusconi P, Zilleruelo GE, Freundlich M. Fibroblast growth factor 23 and lef ventricular hypertrophy in children on dialysis. Pediatr Nephrol 2012; 27:2129-2136.
26. Faul C, Amaral A P, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M. FGF23 induces lef ventricular hypertrophy. J Clin Invest 2011; 121:4393-4408.
27. Saji F, Shiizaki K, Shimada S, Okada T, Kunimoto K, Sakaguchi T, Hatamura I, Shigematsu T. Regulation of fbroblast growth factor 23 production in bone in uremic rats. Nephron Physiol 2009; 111:61-68.
28. Slatopolsky E, Cozzolino M, Lu Y, Finch J, Dusso A, Staniforth M, Wein Y, Webster J. Efcacy of 19-Nor-1, 25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. Kidney Int 2003; 63:2020-2027.
29. Seeherunvong W, Nwobi O, Abitbol CL, Chandar J, Strauss J, Zilleruelo G. Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr Nephrol 2006; 21:1434-1439.
30. Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, Slatopolsky E. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufciency in uremic rats. J Am Soc Nephrol 2007; 18:1796-1806.
31. Amman K, Tyralla K, Gross ML, Schwarz U, Törnig J, Haas CS, Ritz E, Mall G. Cardiomyocyte loss in experimental renal failure: prevention by ramipril. Kidney Int 2003; 63:1708-1713.
32. Ritchie RH, Rosenkranz AC, Kaye DM. B-type natriuretic peptide: endogenous regulator of myocardial structure, biomarker and therapeutic target. Curr Mol Med 2009; 9:814-825.
33. Törnig J, Amann K, Ritz E, Nichols C, Zeier M, Mall G. Arteriolar wall thickening, capillary rarefaction and interstitial fbrosis in the heart of rats with renal failure: the efects of ramipril, nifedipine and moxoni-dine. J Am Soc Nephrol 1996; 7:667-675.
34. Tadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Tompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307:674-684.
35. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Tadhani R, Kang PM. Activated vitamin D attenuates lef ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 2007; 104:16810-16815.
36. Passier RC, Smits JF, Verluyten MJ, Daemen MJ. Expression and localization of renin and angiotensinogen in rat heart afer myocardial infarction. Am J Physiol 1996; 271(3 Pt 2):H1040-1048.
37. Chen S, Gardner DG. Liganded vitamin D receptor displays anti-hypertrophic activity in the murine heart. J Steroid Biochem Mol Biol 2013; 136:150-155.
38. Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Esaki M, Kanamori H, Li L, Ogino A, Ohno T, Kondo T, Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H. Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure. J Card Fail 2007; 13:155-162.